StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
SKIN$0.67-5.33%
Fair $0.67+0.0%

SKIN

SkinHealth Systems Inc.

Consumer Defensive / Household & Personal ProductsNasdaqCM

$0.67

-0.04 (-5.33%)

Fairly Valued+0.0%Fair Value $0.67Fund rank 17/100 · Data gapFallback financials|
SA 19/F
F-Score: 7/9
High DebtDeclining RevenueLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 13%

FCF escenarios

weak_data · normalized FCF $9.3M · quality 13.7/100

Data gap 17/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 13/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

19/100

F

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 7Warnings: 3unknown: 7
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Debt-to-Equity ratio is 6.20, above the 2.0 threshold Revenue has declined for 2 consecutive years ROE is -15.6%, below the 5% threshold
Thesis & Journal · SKINLocal privado en este navegador · SkinHealth Systems Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$86M

P/E

N/A

•

EV/EBITDA

6.1x

↓

ROE

-15.6%

↓

Gross Margin

65.3%

↑

Debt/Equity

6.20

↑
52-Week Range$1
$1$3

TradingView lightweight chart

SKIN price, volumen y niveles de valoración

Último $0.665Periodo -93.9%
Fair value: $0.665

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2019–2025 · 6 años de histórico normalizado

Revenue CAGR

+10.3%

FCF CAGR

—

FCF margin

10.7%

FCF / Net income

-3.40x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $300.8M · net income $-9.5M · FCF $32.3M

2019-FY → 2025-FY

Gross margin

65.3%+1.4% pts

Operating margin

-6.9%-15.0% pts

Net margin

-3.2%-2.2% pts

FCF margin

10.7%+15.0% pts
MetricTTM
2025
2024
2023
2022
2021
2020
2019
Income Statement
Revenue$300.8M$300.8M$334.3M$398.0M$365.9M$260.1M$119.1M$166.6M
Net Income$-9.5M$-9.5M$-29.1M$-100.1M$44.2M$-378.8M$-29.2M$-1.6M
EBITDA$38.7M$38.7M$14.5M$-53.6M$81.6M———
EPS-0.16-0.16-0.23-0.760.23-3.71-0.85-0.05
Gross Margin65.3%65.3%54.5%39.0%68.0%68.6%56.4%63.9%
Operating Margin-6.9%-6.9%-20.3%-32.9%-7.1%-15.4%-14.4%8.1%
Net Margin-3.2%-3.2%-8.7%-25.2%12.1%-145.6%-24.5%-1.0%
Balance Sheet
Debt/Equity6.206.2010.9712.674.50———
Current Ratio1.791.79——————
Cash Flow
Free Cash Flow$32.3M$32.3M$9.3M$8.7M$-124.0M$-39.6M$-15.9M$-7.0M
Returns
ROE-15.6%-15.6%-56.2%-168.6%26.5%-127.1%95.4%135.6%
Valuation
P/E————40.91———
EV/EBITDA6.106.1027.67—19.37———
P/B1.481.483.946.128.37———
Growth & Yield
Revenue Growth-10.0%-10.0%-16.0%8.8%—118.4%-28.5%—
EPS Growth30.4%30.4%69.7%-430.4%—-336.5%-1600.0%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -58.4%

Total return

-58.4%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.23 → -0.16

Residual

-58.4%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-58.4%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.